Engineered immune cells aim to tame childhood arthritis and lupus

NCT ID NCT07490041

Recruiting now Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called KN5601, which uses a patient's own immune cells (NK cells) that have been engineered to target and destroy harmful B cells. The goal is to see if it is safe and can help children aged 5 and older with rheumatic diseases like lupus or arthritis that have not responded to standard treatments. The study will monitor for side effects and check if the disease goes into remission over a year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-CD19/BCMA CAR-NK cells (KN5601)
What this could lead to: If successful, this could point toward a new treatment option for children with severe rheumatic diseases that have not responded to other therapies.
What could go wrong: This is a very early, small study (36 participants) focused on safety. It may not show clear benefit, and there are risks from the cell infusion, including potential severe immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arthritic joint disease juvenile dermatomyositis polyarticular juvenile idiopathic arthritis rheumatic disorder Sjogren syndrome systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE PEDIATRIC RHEUMATOLOGICAL CONDITION (I.E., ARTHRITIS, SLE, KAWASAKI'S DISAESE) RHEUMATIC DISEASES SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

The Children's Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.